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ABSTRACT
Objectives: The aims of this body of work are several fold. Aim 1: To describe the
cerebrospinal fluid (CSF) profile of infants ≤60 days old with bacterial meningitis and
characterize the clinical and laboratory features of infants with bacterial meningitis who
present with no CSF abnormalities. Aim 2: To evaluate the performance characteristics of
the BioFire® FilmArray® Meningitis/Encephalitis panel (ME panel), the only Food and
Drug Administration (FDA)-cleared multiplexed panel for the evaluation of CSF
samples. Aim 3: To identify themes to be included in a parent-reported outcome measure
for febrile infants ≤60 days old and to describe the process of developing a software
application for use with parents of febrile infants ≤60 days old evaluated in the
emergency department.
Methods: Aim 1: Clinical and laboratory data was abstracted from electronic medical
records of infants ≤60 days old with culture-positive bacterial meningitis from 11
children’s hospitals in the U.S. in a 5-year period. Aim 2: A thorough review of the
literature was performed to gather data required for the evaluation of the ME panel. Aim
3: Semi-structured qualitative interviews, as well as design impression and usability
testing of the software application were conducted with parents of febrile infants ≤60
days old evaluated in the emergency department.
Results: Aim 1: The sensitivity of a CSF Gram stain was 71.9% (95% CI: 59.2–82.4),
and the sensitivity of corrected CSF pleocytosis was 80.3% (95% CI: 68.7–89.1) among
infants ≤60 days old with bacterial meningitis. Of 9 infants with meningitis who had a
negative Gram stain result and no corrected CSF pleocytosis, 8 (88.9%) had either an
abnormal peripheral WBC count (>15 000 or <5000 cells per μL) or bandemia >10%.
Aim 2: The ME panel has a pooled sensitivity of 90.2% (95% CI: 86.2-93.1) and
specificity of 97.7% (95% CI: 94.6-99.0). The overall sensitivity for 5 of the 6 bacterial
organisms in the panel was 96.8% (95% CI: 92.7-99.0). Aim 3: After preliminary
qualitative data analysis of interviews with parents, themes for the parent-reported
outcome measure include feeling informed, involvement in decisions, stress, infant and
family outcomes, which emerged as possibilities for further validation. Testing of the
software application has identified elements in the structure, navigability and content to
be modified prior to field testing.
Conclusions: Aim 1: Infants with no CSF pleocytosis and a negative Gram stain result are
unlikely to have bacterial meningitis in the absence of other laboratory abnormalities.
Aim 2: The ME panel is a rapid diagnostic tool with an overall high sensitivity and
specificity for CNS infections, with potential to improve diagnosis and optimize
utilization of healthcare resources. Aim 3: Semi-structured qualitative interviews have
allowed for the preliminary identification of themes to be considered for validation in the
generation of a parent-reported outcome measure of febrile infants ≤60 days of life.
Design impression and usability testing of the application have enabled the identification
of changes needed to optimize the effectiveness of the application for parents of febrile
infants.
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INTRODUCTION
Meningitis is an important cause of morbidity and mortality worldwide.1-3
Although vaccination efforts have made a significant impact in the incidence and
epidemiology of cases in different regions of the world,3-5 in the U.S. alone, there are
several thousand cases of meningitis seen annually in both children and adults.6,7 In other
parts of the world, especially in developing countries, bacterial meningitis has an even
higher impact in terms of incidence, morbidity and mortality.3,8
Several infectious and non-infectious etiologies can cause meningitis.6 Among
infectious etiologies, viral central nervous system (CNS) infections are more common in
the US,6,7 although acute bacterial meningitis is the most rapidly fatal.9 Bacterial
meningitis leads to oxidative damage and alterations in blood flow which cause ischemia
and cortical necrosis. In addition, the immune response to invading bacteria contributes to
hippocampal apoptosis.10 On the other hand, in immunocompetent hosts, viral meningitis
is often benign and self-limited.11
Early introduction of antibiotic treatment in bacterial meningitis is vital. Although
there is limited data in pediatric patients, studies in adults have shown a 10%-30%
increase risk of death or lasting sequelae per hour of treatment delay.12 Suspicion of
bacterial meningitis is a medical emergency, as the mortality rate of untreated bacterial
meningitis is near 100% and even after optimal treatment the disease can still be deadly.5
Evidence also suggests that approximately 20% of patients who survive bacterial
meningitis have long-term disabling sequelae, with hearing loss, seizures, motor deficits
and cognitive impairment being the most common.13
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Given the potential negative consequences of delaying the diagnosis or treatment,
patients suspected of having meningitis are often hospitalized and started on
antimicrobials while awaiting test results.6,7,14,15 These can be unnecessary in patients
with viral meningitis, increasing costs, leading to suboptimal utilization of antimicrobials
and their associated morbidity.16 Studies have also shown that in a significant percentage
of pediatric patients (50-80%) the causative pathogen is not identified, which can lead to
extended hospitalizations and antimicrobial courses due to concern of a bacterial
etiology, which may often be unnecessary.17
The reasons why the causative pathogen is not identified in a large percentage of
patients is likely multi-factorial. Although in part it may be due to the limited number of
viral pathogens targeted by current diagnostic tools, it is potentially also a consequence of
the limitations of diagnostic modalities currently used in the evaluation of patients
suspected of having meningitis. This highlights the need for diagnostic tools with an
enhanced capacity to identify the causative pathogens.
Clinical differentiation between viral and bacterial meningitis is challenging as
the classical signs and symptoms such as headache, fever, photophobia and neck pain are
not specific to a particular etiology.17,18 Cerebrospinal fluid (CSF) culture, Gram stain
and other molecular and cellular analysis of the CSF are often the methods used for the
diagnosis of meningitis.3,9
The sensitivity of CSF culture has been reported to range between 60~90% in
patients with bacterial meningitis, although it varies depending on the organism, and it is
lower in patients pretreated with antimicrobial agents.3,19 Gram stain of the CSF has a
short turnaround time, excellent specificity, is inexpensive and well-validated.3,19
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However, its sensitivity for bacterial meningitis is estimated to be in the range of
35~90%,3,9,20-22 varying significantly depending on the organism, and is also decreased
on patients pretreated with antimicrobials.3,9
Polymerase chain reaction (PCR)-based approaches have been shown to be able
to increase diagnostic yield, capable of identifying viral and bacterial pathogens in the
CSF while having rapid turnaround times.9,19 In fact, viral PCR for enterovirus (EV) and
herpes simplex virus (HSV) have become part of standard care.23 Other methods such as
the latex agglutination test have been used to aid in the rapid diagnosis of bacterial
meningitis however, its sensitivity also varies per organism, and it is decreased in
antimicrobial pretreated samples.3 Its ability to provide additional diagnostic value may
be limited.3,19
Although CSF culture is considered the gold standard for diagnosis, and is
essential to determine antibiotic susceptibilities of the causative pathogen, 3 it can take up
to 72 hours.6,7 In addition, patients can sometimes receive antimicrobials prior to the
lumbar puncture (LP) decreasing the diagnostic yield of the CSF culture.3,19 Hence,
physicians often have to make clinical decisions on the basis of the CSF profile24,25.
Historically, it has been considered that evaluation of the CSF profile of a patient
with bacterial meningitis would show a positive culture, stained smear, an elevated white
blood cell count (WBC) with predominance of polymorphonuclear leukocytes, a reduced
glucose concentration relative to serum, and an increased protein concentration.26,27
However, evidence suggests that patients with bacterial meningitis may have normal or
uncharacteristic CSF profiles. 3,19,28-33 Being able to confidently differentiate bacterial
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from viral meningitis is essential to improve management, and prevent high risk
outcomes and inefficient utilization of healthcare resources.25
Young infants are particularly susceptible to meningitis 7,8,34 and neonates are the
age group most commonly affected by bacterial meninigitis.24 Deficiencies in humoral,
cellular and complement immunity make infants in the first months of life particularly
susceptible to bacterial pathogens. 35 It is estimated that in 2015, 5.942 million children
under the age of 5 died globally, with 2.681 million (45.1%) deaths occurring in the first
month of life.36 Sepsis and meningitis were the 3rd leading cause of death in the first
month of life with over 400,000 deaths, while they represented the 5th leading cause of
death in children under 5 years of age.36
Clinically diagnosing meningitis in young infants can be particularly difficult as
they do not necessarily present with the classic features of the disease.37 Neonates with
bacterial meningitis can often present with symptoms such as irritability, poor feeding,
respiratory distress, changes in skin or tone, while fever is only present in up to 39% of
cases.19 Hence, there is a low threshold to perform LPs in young infants. A recent metaanalysis by Biondi et al. looked into the prevalence of bacterial meningitis in febrile
infants in the first and second month of life, with most studies analyzed being from
patients evaluated in the emergency department. They found that 1.2% of febrile infants
in the first month of life, who underwent CSF testing, were diagnosed with bacterial
meningitis, while only 0.4% of those in the second month of life had the disease.38
It has been a generally accepted practice to perform LPs in all infants in the first
month of life that present with fever of an unknown source, while those in the second
month of life are at a lower risk of bacterial infection and can be risk stratified.38 There is
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ongoing research on the development and validation of clinical prediction rules to help
guide physicians stratify the risk of a serious bacterial infection in infants ≤60days of
age.25,39
The decision to perform invasive studies such as an LP is not always clear. In
fact, there is significant variation on whether to perform an LP on well-appearing infants
≤60 days of life.40,41 Clinical prediction rules aim to provide physicians with evidencebased tools to simplify and increase accuracy in such circumstances,42 however even
though traditionally, clinical success has focused on mortality, physiological measures
and definable clinical events,43 over the last decades the concept of shared decisionmaking has gained strength in the medical field.44 The idea that optimal decisions are
based on a shared decision-making structure, that respects the patient’s preferences,
values and goals45 is rooted in medical ethics when Dr. Robert M.Veatch initially
suggested this model over alternative approaches in 1972.46 In the field of outcomes
research, patients’ experiences and values, are taken into account when evaluating
decisions made in healthcare.43
An important pillar of shared decision-making is the exchange of information
between providers and patients.47 Patients should have a good understanding of the risks,
benefits and treatment alternatives in order to effectively participate in the shared
decision-making process.48 Perceived understanding of information and language
barriers, have been identified as some of the obstacles to shared decision-making on
whether to perform LPs on infants in the first 2 months of life.49
Patient-reported outcome measures assess outcomes from the patient’s
perspective and have been increasingly utilized in clinical practice to monitor and
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improve care.50 Historically, quantitative methods have been used to inform the
evaluation of clinical effectiveness in outcomes research.51 However, these are not
necessarily ideal to measure some of the intricate elements of healthcare delivery, such as
the patient’s perception of quality of care.51 Instead, qualitative methods may be better
suited to examine these aspects of healthcare delivery.45,51
In order to grasp the patient’s perspective, it is vital for patients to take part in the
development of the patient-reported outcome measure.50 For pre-verbal pediatric patients,
parent-reported outcome measures are utilized in order to capture the experience of the
child and family.
This body of work will focus on (i) the study of the clinical and laboratory
features of infants ≤60 days of life diagnosed with culture-positive bacterial meningitis.
(ii) A review the scientific literature to evaluate the the BioFire® FilmArray®
Meningitis/Encephalitis (ME) Panel, a recently FDA-cleared rapid diagnostic tool with
the potential to circumvent some of the current limitations in the diagnosis of meningitis.
(iii) A description of the preliminary results obtained from in-depth, semi-structured
interviews with parents of febrile infants ≤60 days of age, as the initial phase of a larger
study aimed to develop a parent-reported outcome measure for the management of febrile
infants in the emergency department. (iv) Introduce ongoing efforts in the development
of a software application aimed to provide parents of febrile infants ≤60 days of age
relevant and understandable information regarding risks and testing performed in the
emergency department during the evaluation of febrile infants.
All four of these projects aim to address elements of the process of evaluating
infants in the first 2 months of life with concern for meningitis, specifically they are
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associated with the presentation, diagnosis, parental experience and decision-making
components of these evaluations.
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METHODS
I.

Clinical and laboratory features of infants ≤60 days with culture-positive
bacterial meningitis

Study design
This study was a planned secondary analysis of a cross-sectional study of infants ≤60
days of age with bacteremia and/or bacterial meningitis evaluated in the emergency
department of 11 geographically diverse children’s hospital in the United States over a 5year period between July 1, 2011 and June 30, 2016. The study was approved by each of
the 11 children’s hospitals’ institutional review board.
Study sample
For the parent study, each hospital’s microbiology laboratory database or electronic
medical record system was queried for positive blood or CSF culture results obtained in
the ED from infants ≤60 days of age.52
For this secondary analysis the following inclusion criteria had to be met: (i) infants
≤60 days of age evaluated in the emergency department, (ii) diagnosed with bacterial
meningitis, (iii) a CSF culture positive for an a priori–defined bacterial pathogen as
determined by expert consensus 52, these had to be common pathogens (e.g., Group B
Streptococcus, Escherichia coli, Listeria monocytogenes, Streptococcus pneumoniae,
Streptococcus agalactiae, Streptococcus bovis, Klebsiella pneumoniae, Neisseria
meningitides, Pasteurella, Paenibacillus) that were treated as a pathogen by the medical
team (iv) with both CSF WBC and red blood cell (RBC) counts available. Exclusion
criteria: (i) infants with ventriculoperitoneal shunts, (ii) infants with growth of a bacterial
pathogen only from a CSF enrichment broth culture,53 except 1 infant who had CSF
pleocytosis and growth of Listeria monocytogenes from the CSF.
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Data collection
Medical records were used to extract the demographic, historical, physical
examination and laboratory data, including results of a complete blood cell count, the
CSF profile (Gram stain, WBC count and differential, RBC count, protein and glucose
level) and bacterial culture results of urine, blood and CSF.
Definitions
Bacterial meningitis was defined as a CSF culture that grew a pathogen. The
result of the CSF Gram stain was considered positive if bacteria were identified (e.g.,
Gram-positive cocci, Gram-negative rods). CSF pleocytosis was defined as a CSF WBC
count ≥16 cells per mm3 for infants ≤28 days and ≥10 cells per mm3 for infants 29 to 60
days of age.54 For infants with traumatic lumbar punctures (ie, CSF RBC count ≥10,000
cells per mm3), an RBC/WBC correction factor of 1,000:1 was used to determine the
corrected CSF WBC count.55 An abnormal CSF profile was defined as a positive Gram
stain result, CSF pleocytosis, neutrophil predominance on the CSF WBC differential
(>50% neutrophils), an elevated CSF protein level (≥128 mg/dL for infants ≤28 days and
≥100 mg/dL for infants 29–60 days of age),54 or a low CSF glucose level (<25 mg/dL for
infants ≤28 days and <27 mg/dL for infants 29–60 days of age).54 Ill-appearance was
defined by any of the following descriptions on the physical examination in the
emergency department: “ill-appearing,” “toxic,” “limp,” “un-responsive,” “gray,”
“cyanotic,” “apnea,” “weak cry,” “poorly perfused,” “grunting,” “listless,” “lethargic,” or
“irritable”.52

10

Statistical analysis
The sensitivity for bacterial meningitis of the CSF Gram stain and corrected CSF
pleocytosis, alone and in combination was calculated. Proportions were compared by
using the χ2 test or Fisher’s exact test. Statistical analyses were performed by using Stata
version 15.0 (Stata Corp, College Station, TX).
Methods conducted by me
I contributed to the design of the study, interpreted the data, performed the
literature review to inform the writing of the manuscript, drafted the initial manuscript,
and reviewed and revised the manuscript critically for important intellectual content.56
Methods conducted by others
Dr. Aronson conceptualized and designed the study, supervised data collection
locally and nationally, performed the data analyses, interpreted the data, helped draft the
initial manuscript, and reviewed and revised the manuscript critically for important
intellectual content. Dr. Neuman and Dr. Wang contributed to the design of the study,
collected local data, interpreted the data, and reviewed and revised the manuscript
critically for important intellectual content. Dr. Nigrovic, Dr. Desai, Dr. DePorre, Dr.
Leazer, Dr. Marble, and Dr. Sartori collected local data, interpreted the data, and
reviewed and revised the manuscript critically for important intellectual content.
II.

Review of the literature and evaluation of the BioFire® FilmArray®
Meningitis/Encephalitis (ME) Panel

Study design
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A thorough review of the literature was conducted to gather information related to
multiplexed arrays, rapid diagnostics, case reports and published studies that have used
and evaluated the BioFire® FilmaArray® ME Panel. Google Scholar was the search
engine utilized to gather all the reviewed scientific literature about the ME panel.
Inclusion criteria was any published work that referenced the ME panel. Search terms
included “BioFire”, “FilmArray”, “ME panel”, “multiplexed arrays”.
Data collection
Data was collected from published scientific literature. For calculations and
statistical analysis, data was extracted from a published systemic review and metaanalysis of the ME panel by Tansarli et al.23
Statistical analysis
Statistical analyses were performed using Stata version 15.0 (Stata Corp, College
Station, TX) and Microsoft® Excel® (2013).
Methods conducted by me
I gathered and reviewed the published scientific literature, assisted with the
statistical analyses, interpreted the data, drafted the initial manuscript, and reviewed and
revised the manuscript critically for important intellectual content.
Methods conducted by others
Dr. Aronson supervised the gathering and review of published scientific literature,
performed statistical analyses, interpreted the data, helped draft the initial manuscript,
and reviewed and revised the manuscript critically for important intellectual content.
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III.

Qualitative study to better understand the experience of parents of febrile
infants ≤60 days of age evaluated in the emergency department

Study design
This qualitative study was performed through the recruitment and interviews of
parents of febrile infants ≤60 days of age that presented to Yale-New Haven Children’s
Hospital over an approximate 4 month period between August and December of 2019.
This study was approved by the hospital’s institutional review board, and a written
informed consent was obtained from each of the participants during enrollment in the
study. A small monetary ($25 gift card) incentive was provided to those who agreed to
participate.
Study sample
Through monitoring of the electronic medical record system and notifications
from physicians working in the emergency department at Yale New Haven Children’s
Hospital, parents that presented with febrile infants ≤60 days of age (fever defined as a
temperature ≥ 100.4 °F) were approached and informed consent was obtained from those
who agreed to participate. In order to ensure diversity of socio-demographic
backgrounds, purposeful sampling was performed. In addition, parents whose primary
language was Spanish were also enrolled.
Data collection
Semi-structured interviews were conducted with those enrolled in the study, and
these interviews were audio-recorded, transcribed, and qualitatively analyzed until
thematic saturation was achieved. Demographic data was obtained from each parent
enrolled and included: age, gender, race/ethnicity, number of children, prior visits to the
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emergency department with a febrile infant, highest level of education, and health literacy
by asking the parent’s confidence in completing medical forms by his/herself.
Information relevant to the infants was gathered through the electronic medical
record and included: gender, age, whether an LP was performed, whether the patient was
admitted, results of urine, blood and CSF cultures (if performed), and viral test results (if
performed).
Interviews
The semi-structured interviews were performed by Dr. Paul Aronson (pediatric
emergency physician at Yale New Haven Children’s hospital) and/or myself. All
interviews were conducted individually except in the occasions where both parents of an
infants participated jointly. All interviews performed in English were transcribed wordby-word by professional transcribers. All interviews conducted in Spanish were
transcribed and translated by me. An interview guide was used to conduct the interviews.
Interview questions aimed to understand the parents’ experience with the evaluation of
febrile infants ≤60 days of age in the emergency department, factors related to parents’
stress during the process, and the outcomes important to parents (Table 1).
Data Analysis
Dr. Aronson, Ms. Paula Schaeffer (a research associate with expertise in
qualitative research) and myself, reviewed the transcripts separately and subsequently
discussed our analysis to reach a consensus. We developed an initial coding guide based
on topics that arose during interviews; the guide was iteratively revised during the
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process of data analysis. The data was then coded using the grounded theory approach57
until thematic saturation was obtained (after 21 interviews).
Methods conducted by me
I contributed in the monitoring of the electronic medical record, enrollment of
parents in the study, performing and recording of interviews, transcription and translation
of interviews conducted in Spanish, analysis and coding of interviews and initial
interpretation of obtained results.
Methods conducted by others
Dr. Aronson conceptualized and designed the study, supervised data collection,
developed the interview guide, contributed to the monitoring of the electronic medical
record, enrollment of parents in the study, performing and recording of interviews,
analysis and coding of interviews and initial interpretation of obtained results. Ms. Paula
Schaeffer collaborated on the development of the interview guide and in the analysis of
interviews.
IV.

Development of a software application to provide relevant information to
parents of febrile infants in the emergency department

Study design
This study is part of an ongoing research project. The parts described in this body of
work were done in two phases. The first in September of 2019 and the second in January
and February of 2020. Both phases were conducted with Yale New Haven Children’s
Hospital’s pediatric emergency physicians and nurses, as well as with parents of febrile
infants ≤60 days of life evaluated in the emergency department. For the phase two
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(usability testing), a small monetary ($35 gift card for parents, $10 for physicians and
nurses) incentive was provided to those who agreed to participate.
Study sample
Design impression testing of a software application was performed through an
online survey distributed to pediatric emergency medicine physicians, nurses and parents
of febrile infants ≤60 days of life evaluated in the emergency department. The objective
was to assesses if the visual format of the application supported the message it intends to
communicate. During design impression testing, participants had 5 seconds to observe
some of the different designs presented in the application and provide their immediate
“gut” reaction to the layout (not the content), by listing their perceptions about the
message the design intended to communicate. Subsequently, a randomized list of both
“positive” and “negative” adjectives was provided to participants for them to select which
ones they considered best described the displayed designs. This data was then used to rate
the application design as overall “positive” or “negative”.
Usability testing of the software application was performed through in-person
sessions with pediatric emergency medicine physicians, nurses and parents of febrile
infants. These sessions included a qualitative and a quantitative analysis component. For
the qualitative assessment participants were given an iPad and a Yale ITS UX Researcher
provided a scenario in order to assess their ability to navigate the application and find
relevant information. Participants were asked to “think aloud” while using the
application. Subsequently the investigators asked a set of questions related to the format
and content of the application. Quantitative assessment was then performed by gathering
the rating of each participant regarding the application’s ease of use on a scale of 1 (very
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difficult) to 7 (very easy), and by having each participant complete the System Usability
Scale, a 10-item validated questionnaire for usability testing, scored from 0-100,58 with
high scores being indicative of increasing usability.59,60
Data collection
Information was collected based on overall design impression of the software
application, easiness of use, understanding of content, real-time navigation and overall
general feedback.
Methods conducted by me
I contributed to recruiting and enrolling parents to participate in the studies,
collaborated in the usability testing sessions, and translated the initial version of the
software application from English to Spanish.
Methods conducted by others
Dr. Aronson conceptualized and designed the study, created the content and
format for the software application, supervised data collection, contacted and enrolled
parents, physicians and nurses, performed the usability testing sessions, gathered and
interpreted the data. Yale Information Technology Services (ITS) User Experience and
Design services team provided the technical expertise to design and develop the software
application, and interpreted the design impression testing and usability testing data.
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STATEMENT OF PURPOSE
As described above, there is a low-threshold to perform CSF testing in infants ≤60
days of life when there is a possibility of bacterial meningitis, due to their increased
susceptibility and subtle presentation. Given that physicians often rely on the CSF profile
when making management decisions, and that the CSF profile of patients with bacterial
meningitis can sometimes be normal, an improved understanding of the clinical and
laboratory features of infants ≤60 days of life with bacterial meningitis could help in the
management of those who undergo CSF evaluation. For the first part of this body of
work, the aim is to describe the CSF profile of infants ≤60 days of life with culturepositive bacterial meningitis that were evaluated in the emergency department, and to
describe the clinical and other laboratory characteristics of those that presented without
other CSF abnormalities.
The case for faster and more sensitive tools to elucidate the causative pathogen in
meningitis, as well as the need for new tools that can help providers make more informed
decisions when differentiating between viral and bacterial meningitis, has also been
demonstrated above. The second part of this body of work is focused on the evaluation of
the benefits and limitations of the BioFire® FilmArray® ME Panel, a recently FDAcleared technology that shows promise in enhancing our ability to overcome some of the
existing limitations in our current diagnostic approach. In addition, promising alternative
new methods that also have the potential to significantly change our methodology in the
diagnosis of meningitis are briefly explored.
Third, the decision to perform CSF studies in febrile infants ≤60 days of life is not
necessarily an easy one. The prevalence of bacterial meningitis in this population is
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approximately 1% of those with CSF studies performed. In addition, there is significant
variability on whether to perform an LP on a well-appearing infant in the first 2 months
of life. Ongoing research aimed at better understanding and stratifying patients to rule-out
bacterial meningitis is essential to avoid unnecessary procedures, hospitalizations,
antimicrobial exposure and healthcare costs. At the same time, it is evident that in
addition to the clinical ramifications that must be considered when taking the decision to
perform invasive CSF studies, it is essential to take into account the parent’s values,
preferences and goals. To our knowledge, no parent-reported outcome measure for febrile
infants currently exists. The initial phase for the development of such outcome measure,
is the basis of the project described in the third part of this body of work.
We hypothesize that (i) there are a set of factors that parents of febrile infants ≤60
days of life evaluated in the emergency department value when defining a good outcome.
(ii) These set of factors could be identifiable through in-depth, semi-structured interviews
with parents, and qualitative data thematic analysis. The end-goal of this project is to
identify themes and items to be included in a parent-reported outcome measure of febrile
infants ≤60 days of life.
Finally, as described above, parents’ perceived understanding of information and
language barriers in the exchange of information between providers and parents, have
been identified as barriers for shared decision-making in the emergency department
setting during the evaluation of febrile infants in the first 2 months of life. The final part
of this body of work is focused on the development and initial testing of a software
application to be provided to parents of febrile infants while in the emergency
department. The aim is for this application to serve as an additional (not as a substitute)
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source of information about what are the risks, testing and possibilities associated with
the presentation and management of their infant. This could significantly impact the
experience of parents in the emergency department, by having a trustable informational
resource, specifically written for individuals not involved in the medical flied. This could
potentially help overcome some of the identified barriers in the shared decision-making
process. The main objective of this part of the project is to test the design, content, and
navigability of the application with those involved in the shared decision-making process
(i.e., pediatric emergency medicine physicians, nurses and parents).
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RESULTS
I.

Clinical and laboratory features of infants ≤60 days with culture-positive
bacterial meningitis

Over the study period, 10,635 infants ≤60 days of age had CSF cultures obtained, and
76 (0.7%) had positive culture results. Ten of these 76 infants (13.2%) were excluded: 3
had ventriculoperitoneal shunts, and 7 did not have CSF cell counts performed. Of the
remaining 66 study infants with bacterial meningitis, 44 (66.7%) were ≤28 days, and 22
(33.3%) were 29 to 60 days of age.
The most commonly isolated pathogens were Group B Streptococcus (GBS) (n = 41
[62.1%]), Escherichia coli (n = 8 [12.1%]), and Listeria monocytogenes (n = 4 [6.1%]).
The distribution of pathogens was different between infants ≤28 days and those 29 to 60
days of age (P = .03). Forty-eight infants (72.7%) had concomitant positive blood culture
results with the same bacterial pathogen.
Overall, 62 of 66 infants with bacterial meningitis had an abnormal CSF parameter
(93.9%; 95% confidence interval [CI]: 85.2–98.3) (Table 2). The sensitivity of the CSF
Gram stain for bacterial meningitis was 71.9% (95% CI: 59.2–82.4). After correction of
CSF WBCs for CSF RBCs, the sensitivity of CSF pleocytosis for bacterial meningitis
was 80.3% (95% CI: 68.7–89.1). The sensitivity of combining a positive Gram stain
result with corrected CSF pleocytosis was 86.4% (95% CI: 75.7–93.6). The proportion of
infants with a positive Gram stain result or corrected CSF pleocytosis was the same
among infants ≤28 days and infants 29 to 60 days of age (86.4% vs 86.4%; P = 1.0)
(Table 2). Among infants who were not ill appearing, the sensitivity of combining a
positive Gram stain result with corrected CSF pleocytosis was 81.3% (95% CI: 63.6–
92.8).
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A total of 9 infants with bacterial meningitis had a negative CSF Gram stain result
and no CSF pleocytosis (3 of whom had no pleocytosis only after correction of CSF
WBCs for CSF RBCs). Six infants (66.7%) were ≤28 days, and 3 (33.3%) were 29 to 60
days of age. Pathogens isolated from the CSF of these infants were GBS (5 infants),
Escherichia coli (2 infants), Staphylococcus aureus (1 infant), and Klebsiella oxytoca (1
infant). Five infants (55.6%) had concomitant bacteremia. No infants had low CSF
glucose levels, whereas 5 (55.6%) had an elevated CSF protein level (Table 3).
Of the 9 infants, 8 (88.9%) had either an abnormal peripheral WBC count (>15 000 or
<5000 cells per mL) or bandemia >10% (Table 3). The other infant was 42 days old and
had Escherichia coli bacteremia and meningitis and no CSF pleocytosis after correction
of CSF WBCs for RBCs. The infant was not ill appearing, had a normal peripheral WBC
count, and had an absolute neutrophil count of 4599 neutrophils per mm3, without a band
count performed.
II.

Review of the literature and evaluation of the BioFire® FilmArray®
Meningitis/Encephalitis (ME) Panel

In October, 2015, the FilmArrary® Meningitis/Encephalitis Panel (ME) (BioFire Salt
Lake City, UT) was the first FDA-cleared multiplex PCR panel for the evaluation of CSF
samples.61,62 The ME panel is a multiplexed PCR able to identify 14 organisms, which
include 7 viruses, 6 bacteria, and 1 fungus (Table 4).63 The ME panel consists of
automated nucleic acid extraction, purification, reverse transcription, PCR, DNA melting
analysis and automatic results analysis.61,63 A minimum of 0.2 mL of CSF volume is
needed, the ME panel is capable of analyzing 12 samples at a time, and less than 2
minutes of hands-on technician time are required. Most important for clinicians is that
results are obtained in approximately 1 hour.61 Notably, the ME panel is intended to be
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used jointly with additional clinical, epidemiological and laboratory data, including CSF
culture.63 Additionally, the panel is not intended for CSF specimens collected from
indwelling CNS medical devices63,64 or from patients in whom there is concern for a
nosocomial infection, as pathogens which often cause these infections are not included in
the ME panel.65
There have been multiple investigations that have evaluated the ME panel for the
detection and identification of pathogens in pediatric and adult patients assessed for
meningitis/encephalitis. The largest prospective study to date by Leber et al, evaluated
1,560 CSF samples, and the sensitivity of the ME panel ranged from 85.7% for HHV-6 to
100% for 9 of the 14 organisms. However, there were limited numbers of samples for
many of the organisms and two (Listeria monocytogenes and Neisseria meningitides)
were not detected in the study. The specificity of the ME panel was reported to be 99.2%
or greater for all 14 organisms.66
A recent meta-analysis by Tansarli et al. identified 8 studies (prospective and
retrospective focused solely on pediatric or both pediatric and adult patients) that provide
data required to estimate the performance of the ME panel through the evaluation of
discordant results between the ME panel and reference methods. Using the data from the
meta-analysis, we calculated the overall performance characteristics of the ME panel
from the 8 studies (Table 5). Additionally, we calculated the combined performance
characteristics for the ME panel: pooled sensitivity 90.2% (95% CI: 86.2-93.1),
specificity 97.7% (95% CI: 94.6-99.0), positive predictive value (PPV) 85.1% (95% CI:
81.6-88.2), negative predictive value (NPV) 98.5% (95% CI: 97.9-98.9), likelihood ratio
positive (LR+) 38.8 (95% CI: 16.6-90.8), likelihood ratio negative (LR-) 0.10 (95% CI:
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0.07-0.14). Due to the limited number of studies and sample sizes, the authors of the
meta-analysis were not able to calculate sensitivities and specificities of the ME panel for
individual organisms in the panel.23
From the data gathered by Tansarli et al. from these 8 studies, we also calculated that
the overall sensitivity for 5 of the 6 bacterial organisms in the ME panel was 96.8% (95%
CI: 92.7-99.0). As the 1 positive case of Listeria monocytogenes was not able to be
corroborated, we were not able to include this organism in the calculation of overall
sensitivity for the bacterial pathogens in the panel.23
Young infants <3 months of age are particularly susceptible to ME.7,8,34 Although
many studies evaluating the ME panel have included infants in the first 3 month of life,
65-80

2 of the investigations specifically focused on this age group. 78,80 Arora et al.

evaluated the ME panel in 62 infants ≤3 months of age and reported a sensitivity of 100%
and specificity of 93.4%. Blaschke et al., however, reported mixed results for infants ≤60
days of age, including two false positive bacterial pathogens detected by the ME panel.
Additionally, larger number of infants had viruses detected with the ME panel than with
conventional methods, but it was unclear if these detections were true positive or false
positive results.
The duration of antimicrobial therapy with the implementation of the ME panel has
also been evaluated. A study in a pediatric population found a shorter duration of
antimicrobial therapy after the implementation of the ME panel (2 vs. 3 days).73
Additionally, in a study focused on partially-treated bacterial meningitis in adult and
pediatric patients, the total duration of antimicrobial treatment was shorter with
implementation of the ME panel (9.5 days vs. 15.2 days).81 A shorter time to narrowing
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antimicrobials and a decrease in the number of acyclovir doses has also been reported
with use of the ME panel,79 as has an increase in use of narrow spectrum regimens.81
Other studies, however, have provided conflicting results, including a study of adult
patients that reported no difference in the duration of antimicrobial therapy with the use
of the ME panel.82 As a possible mechanism for these findings, some investigations
found that significant proportion of patients with negative ME panel results were still
continued on antimicrobial therapy.72,82 The potential impact of the implementation of the
ME panel on hospital length of stay has also been analyzed. While some studies have
reported a shorter duration of hospitalization with use of the ME panel,73,79,83 others have
found no difference.81,82
III.

Qualitative study to better understand the experience of parents of febrile
infants ≤60 days of age evaluated in the emergency department

Of the 21 febrile infants whose parents were enrolled in the study, 8 (38.1%) were
≤28 days of age, while the remaining 13 (61.9%) were 29-60 days of life. The median
age of the infants was 35 days (range 3 to 60 days). Of the 21 patients, there were 9
females (42.9%) and 12 male infants (57.1%). LPs were attempted on 15 (71.4%) of them
and were successful on 12 (80.0%). The presentation to the emergency department lead
to a hospital admission in 19/21 (90.5%), while 1 of the 2 patients discharged was
admitted after presenting for a second time to the emergency department. Of the 21
infants evaluated, 1 was diagnosed with culture-positive bacterial meningitis (due to
Neisseria meningitides).
Out of the total 21 parental interviews, 11 (52.4%) were conducted on mothers, 3
(14.3%) were conducted on fathers, and 7 (33.3%) with both the mother and father
jointly. A total of 4 parents (19.0%) had interviews in Spanish as this was the language
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preferred by the parents, of these 4 Spanish speaking parents, 3 (75.0%) were mothers
and 1 (25.0%) was a father. The remaining 17 parents (81.0%) had interviews conducted
in English. The median number of days from the emergency department visit to the day
the interview was conducted was 1 (range 0 to 9 days).
Several concepts were identified when evaluating for a set of items to be considered
in the generation of a parent-reported outcome measure. Although the analysis process of
all the interviews has not yet been completed, there are a few areas that were recurrent
through many of our interviews and will likely be associated with some of the themes to
go onto the process of determining the items for inclusion in the parent-reported outcome
measure. Some of these identified in a preliminary analysis include: (1) feeling informed,
(2) involvement in decisions, (3) stress, (4) infant outcomes and (5) family outcomes
(Table 6).
IV.

Development of a software application to provide relevant information to
parents of febrile infants in the emergency department

Design impression testing of the application was successfully completed through the
input of pediatric emergency medicine physicians, nurses and parents that had presented
to the emergency department with a febrile infants ≤60 days of age. A total of 10
participants completed the testing, and their “gut” impressions were, overall, positive, as
interpreted by Yale ITS. Therefore, the designs of the application were determined to be
ready for incorporation into a prototype of the application. The software application was
then developed. Subsequently, usability testing has so far been conducted with 2 pediatric
emergency medicine physicians, 1 pediatric emergency nurse, and 4 parents of febrile
infants. Additionally, 2 other parents are scheduled to perform usability testing this
upcoming week. Overall, the application has been highly rated for its usability, and all
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the participants felt the application would be helpful for parents. Three main concepts for
revisions have been identified in the preliminary results of usability testing. The layout in
some areas of the application must be adjusted as some of the participants in the study
noted they failed to realize there was additional content in parts of the application. There
have also been suggestions in terms of navigability between pages of the application that
will likely be implemented in the next iteration. Finally, some of the information
provided in the application will likely be edited following the feedback provided by
physicians, nurses and parents that have participated in the testing of the application.
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DISCUSSION
I.

Clinical and laboratory features of infants ≤60 days with culture-positive
bacterial meningitis
In this multicenter cross-sectional study, the majority of young infants with

bacterial meningitis who were evaluated in the ED had either a positive Gram stain result
or corrected CSF pleocytosis. Of the few infants with bacterial meningitis without these
laboratory markers, all but 1 had either an abnormal peripheral WBC count or bandemia.
We found that CSF pleocytosis had a sensitivity of 80.3%, which is higher than
reported in some recent studies.28,55 Our study builds on this previous work by revealing a
higher sensitivity (86.4%) when CSF pleocytosis was combined with a positive CSF
Gram stain result.
The bacterial meningitis score combines clinical and laboratory features to
accurately identify infants with CSF pleocytosis at low risk for bacterial meningitis.84
However, although this validated score has 100% sensitivity in infants ≤60 days of age, it
has a specificity of 1.6% and should not be applied clinically in this age group.85
Therefore, these youngest infants with CSF pleocytosis are often treated presumptively
for bacterial meningitis until the results of CSF bacterial cultures are available. Although
a minority of infants with bacterial meningitis in our study had normal CSF profiles, they
frequently had either an abnormal peripheral WBC count or bandemia. Our results,
combined with the overall low prevalence of bacterial meningitis (1%) among infants
who undergo CSF testing,38 reveal that infants with no CSF pleocytosis and a negative
Gram stain result are unlikely to have bacterial meningitis in the absence of other
laboratory abnormalities.
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Traumatic lumbar punctures artificially elevate the CSF WBC count by
introducing peripheral blood into the spinal space (which could have resulted in the
positive CSF culture result for the infant with no CSF pleocytosis, a normal Gram stain
result, and growth of Escherichia coli in the blood and CSF). Correcting CSF WBCs for
the presence of RBCs reduces the sensitivity for bacterial meningitis, whereas it increases
the specificity.55 In our study, applying a CSF RBC/WBC correction factor of 1,000:1
classified 3 additional infants with bacterial meningitis as having no CSF pleocytosis.
However, the peripheral WBC count, band count, or CSF protein level was abnormal in
these infants. When applying a CSF RBC/ WBC correction to young infants with
traumatic lumbar punctures, clinicians should consider additional laboratory parameters
when making management decisions.
Limitations
Our study has several limitations. First, we only included infants with a positive
CSF bacterial culture result. We excluded 13 infants with bacteremia and CSF
pleocytosis but negative CSF culture results after antimicrobial pretreatment because of
potential misclassification of these infants as having bacterial meningitis. Second, CSF
pleocytosis and an abnormal peripheral WBC count or elevated band count are not
specific for bacterial meningitis, and we do not know the overall number of infants with
these laboratory abnormalities. Therefore, our findings are most applicable when
clinicians have clinical concern for bacterial meningitis, but the infant has a normal CSF
profile. Third, our study was conducted at pediatric emergency departments, and our
findings may not be generalizable to other settings. Fourth, we could not assess
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abnormalities in newer biomarkers because only 4 infants had a procalcitonin level
measured, and 12 had a C-reactive protein measurement obtained.
II.

Review of the literature and evaluation of the BioFire® FilmArray®
Meningitis/Encephalitis (ME) Panel

Multiplexed PCR technologies allow for the simultaneous detection and identification
of microorganisms in a single test reaction. Currently there are multiple FDAcleared/approved multiplex PCR respiratory, gastrointestinal and blood panels.61,62
Although for years there have been FDA-approved PCR technologies to test for either
enteroviruses or herpes simplex virus1/2, in October, 2015, the ME panel was the first
and so far only FDA-cleared multiplexed PCR for the identification of bacteria, virus and
fungi in the CSF.
Benefits and Limitations of the ME Panel
There are multiple potential benefits and limitations of the ME panel (Table 7).
Potential clinical benefits include the detection of CSF viruses and bacteria with high
sensitivity and specificity, as noted previously. 23 Additional clinical benefits reported in
the literature include shorter time to pathogen identification,73,75,86 detection of organisms
in CSF missed by other conventional studies such as Gram stain 87,88 or culture,71,80,89-91
identification of organisms in samples of patients pretreated with antimicrobial
agents,71,80,81,87,88 and enhanced implementation of chemoprophylaxis for close contacts.81
There is also a possible economic impact of using the ME panel. Given the adverse
consequences of delayed or misdiagnosed meningitis/encephalitis, patients suspected of
ME are often hospitalized for empiric antimicrobial therapy while awaiting the results of
CSF culture.14,15,83 Fast turnaround times of the ME panel (approximately 1 hour) have
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the potential to optimize resource utilization by decreasing unnecessary hospitalizations,
14,15

number of other diagnostic tests, 14,15,92 length of stay,14,15,73,79,83,92 and length of

empiric antimicrobial therapy. 14,15,92 Theoretical models in pediatric and adult patients
have suggested that the ME panel can lead to cost savings when compared with current
practice standards.14,15 A study in adult patients found a significant difference between
the median costs per treatment course of antimicrobials for patients who received
standard of care testing compared with those in which the ME panel was used.93 Another
study estimated cost savings of approximately $1,750 per case with the use of the ME
panel in patients with suspected CNS infections, due to faster turnaround times
comparted with conventional methods.83 These potential cost savings must be evaluated
while also taking into account the cost of purchase of the ME panel, the testing itself, and
the service of the equipment.83,93 The elevated cost of performing each test has been
considered a limitation for the implementation of the ME panel in low-income
countries.68
There are important limitations of the ME panel. Some investigators have raised
concerns for false positives23,66,94,95 and false negatives23,66,94,96,97 with use of the ME
panel. Case reports have described how false positive and/or false negative ME panel
results led to delayed diagnosis of the causative pathogen.95,96 Studies have also
suggested that the ME panel should not replace the cryptococcal antigen test23,89,94,96 and
culture23,96 for patients with suspicion of C. neoformans/C. gattii ME. Specifically, some
potential false negative results of C. neoformans/C. gattii on ME panel have occurred in
patients with low burden of disease96,98 and/or in patients on antifungal treatment.23,63,66,96
Additionally, studies have suggested the possibility that positive antigen results after
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initiation of therapy may indicate persistence of antigen and not actual detection of live
organisms.63,66,99 False negative results for viruses may be due to specimens containing
low viral loads86 and to the lower ability of the ME panel to detect viruses when
compared to some singleplex assays.75,94,100,101 With regards to false positive results, there
are concerns for the potential of contamination during collection and processing of CSF
samples.23,66
It is also important to highlight that all herpesviruses in the ME panel (HSV-1, HSV2, CMV, VZV, HHV-6) can establish latent infections. Therefore, a positive result in the
ME panel may be due to a primary infection, or alternatively to a latent infection present
in the cells retrieved in the specimen (either the CSF or from peripheral blood in a
traumatic tap) or reactivation of the virus (with or without true disease).66,94,102 This
accentuates the importance of evaluating the full clinical scenario when interpreting ME
panel results.23,66,103,104 In addition, HHV-6 can be integrated into human chromosomes
and transmitted vertically giving a positive ME panel result.86,103
Clinicians should consider the entire clinical scenario including immune status of the
patient, symptoms, laboratory, and imaging data when dealing with a positive FilmArray
test 95,103. For example, most cases of HHV-6 encephalitis occur 2-6 weeks after
hematopoietic stem cell transplants and in other immunocompromised states 64,103. In the
initial investigator use only (IUO) version of the FilmArray, Epstein-Barr Virus (EBV)
which can also establish latency or be reactivated, was one of the targets of the panel.
Due to concerns for the discordance of results and the possibility of misleading clinicians,
it was taken out of the commercial version approved by the FDA 66. Some have also
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questioned the significance of a positive result for other viruses in the panel (such as
HHV-6 and CMV) 64,74,104.
Promising Additional Rapid Diagnostic Technologies
Multiplexed PCR panels, like the BioFire® FilmArray® ME Panel, are one of
several rapid diagnostic approaches that have the potential to overcome some of the
existing limitations in the diagnosis of CNS infections. Some of these diagnostics employ
different PCR-based techniques to improve the diagnostic yield such as, the utilization of
nested-PCR (as in the BioFire® FilmArray®), loop-mediated isothermal amplification
(LAMP),105 and 16s ribosomal RNA sequencing (broad-range PCR).106 Others employ
different approaches for the identification of microorganisms such as matrix-assisted
laser desorption ionization-time-of-flight mass spectrometry (MALDI-TOF).107 and
metagenomics next-generation sequencing.108 All of these offer promising avenues to
improve our current strategies to diagnose CNS infections, but require further research.
III.

Qualitative study to better understand the experience of parents of febrile
infants ≤60 days of age evaluated in the emergency department

The preliminary results of the in-depth, semi-structured interviews with parents of
febrile infants, show the emergence of concepts that will potentially be used in the
subsequent stage of the project (identification and validation of themes) once the analysis
of the current qualitative data is finalized (and results are no longer preliminary).
The concept of feeling informed was an interesting one that presented with some
variability. Although many parents felt providers were in constant communication, and
that they had a good understanding of what was going on, others mentioned an element of
surprise when they were told they were going to be admitted. Interestingly, some also
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noted that providers often repeated the information, which they found to be helpful.
Although it is difficult to assess the level of understanding parents had at the time, it
seems most parents felt they were informed by their providers.
When considering the amount of information that is provided to parents regarding
testing and risks, it is also important to realize the emotional states parents often
described while being in the hospital. Experienced emergency department providers have
likely seen these presentations many times in their careers, however understanding the
emotions parents are describing can potentially be an essential pillar when aiming to
enhance shared decision-making and improve the parents’ experience during the medical
evaluation of their children.
Given that the approach to febrile infants in the first month of life can be different
with regards to CSF studies when compared to those in the second month of life38, it was
expected to observe variability in the parents’ perspective regarding their involvement in
making some of the decisions associated with their children. Interestingly however, there
was also variability within parents of infants in the second month of life. While some felt
their opinion was considered and listened too, others felt less part of the decision.
When analyzing the factors that either increased or decreased the level of stress,
parents often cited the compassionate and kind care of providers (with a special emphasis
given to nurses) as one of the main factors allowing them to feel less stressed. Parents
also appreciated when the staff would place emphasis not only on the patient but also on
the parents’ experience. On the other hand, uncertainty, the wait and watching the testing
being done on their children (especially when the blood draws, LPs or IVs were
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unsuccessful) were some of the main factors that worsened their stress levels while in the
hospital.
Given the multiple potential etiologies of fever in infants, it was also expected for
variability to be observed in parental perceptions on whether their babies were doing well
or not well at the time the interviews were conducted. Interestingly many parents
expressed improvement on their perception of their baby’s health when compared to their
initial presentation, however some noted evident changes in their baby’s heath-status
when compared to baseline.
Another interesting concept that can often be overlooked is the impact that this
experience can have in families. Not just the emotional toll and potentially traumatic
experience of witnessing the tests required to be performed on their infants, but also on
other things that can become and additional sources of stress and worry for parents.
These include the need to find childcare for other their children while being in the
hospital, the need to miss work, or financial concerns associated with the care received.
In 1964 Green and Solnit described the concept of the vulnerable child syndrome
(VCS). They reported cases of healthy children that experienced life-threatening events in
which their parents expected fatal results, and how this impacted the psychological
development and parent-child relationship in the long term.109 Others have studied the
impact of the VCS in emergency department usage.110
The potential impact of the parents’ experience during the evaluation of a febrile
infant to rule-out bacterial meningitis could have more significant and long-term
consequences that we are currently aware. We tried to explore how such experience

35

would influence the parents’ future reactions to changes in the health-status of their
children. However, a better understanding of the long-term impact that the evaluation of a
febrile infant can have in the parent-child relationship and the long-term consequences (if
any) this experience can have in the development of the child, could provide further
insights into the appropriate information and resources that physicians could provide to
parents to offer optimal care.
It is important to note that the results of this project presented in this body of work
need to be finalized before generating a final list of themes and items to be validated for
inclusion in a parent-reported outcome measure.
Limitations
Interviews were conducted at a single, tertiary-care children’s hospital. However,
we enrolled parents from different race/ethnicities, ages, genders, and levels of education
and preferred language. In addition, interviews were conducted in only two languages
with most of them being done in English. This means our results might not be
generalizable to the entire population of parents of febrile infants. Our goal is for this to
serve as an initial study upon which further research could be done to eventually create a
parent-reported outcome measure that better represents the diversity of our society.
In addition, parents were interviewed shortly after being admitted or discharged
from the hospital. Although this may have provided a fresh perspective, their answers
might have also been influenced by the emotional state associated with their presentation.
For this reason, the validation of results with parents (months after the original interviews
were conducted) and other healthcare providers will be important.

36

IV.

Development of a software application to provide relevant information to
parents of febrile infants in the emergency department

Usability testing is an important step when creating interactive, user-centered tools to
evaluate the effectiveness, efficiency, and appropriate responses in projected users.111
After completion of the usability testing part of the project, important changes will be
implemented to the structure, navigability and content of the application based on
obtained results. Following these changes, field testing of the application will be
performed in order to evaluate the impact of this tool in the medical encounter,
specifically on parents’ knowledge and experiences, and to facilitate a shared decisionmaking process between physicians and parents.
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CONCLUSION
Most infants ≤60 days of age with bacterial meningitis have either CSF
pleocytosis or a positive Gram stain result. Among infants with normal CSF profiles,
bacterial meningitis is rare, and clinicians should consider the results of additional
laboratory parameters in making treatment decisions.
The BioFire® FilmArray® Meningitis/Encephalitis Panel is the first FDA-cleared
multiplexed PCR capable of simultaneously detecting and identifying 14 organisms in
CSF samples. This newer rapid diagnostic tool has an overall high sensitivity and
specificity for CNS infections and has the potential to improve diagnosis and optimize
utilization of healthcare resources for patients undergoing evaluation of meningitis.
However, the ME panel should not be used as the sole diagnostic tool in patients with
suspected bacterial meningitis, and clinicians should interpret ME panel results in
combination with clinical, epidemiological and laboratory data. Additionally, both false
positive and false negative results have been reported. A negative ME panel test does not
indicate the absence of infection, as only 14 organisms are included in the panel, and a
positive test may not necessarily reflect the true disease-causing organism, such as with
latent viral infections. More research is needed to guide laboratories and clinicians in
determining the optimal use of the ME panel in clinical decision-making for patients
undergoing evaluation for CNS infections.
Semi-structured qualitative interviews have allowed for the preliminary
identification of important themes to be considered for validation in the generation of a
parent-reported outcome measure for febrile infants ≤60 days of life. Further analysis and
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interpretation of the obtained results is essential to determine the appropriate set of
themes to be included for validation.
Design impression and usability testing of an application to provide relevant
information to parents during the evaluation of febrile infants in the emergency
department has already provided valuable data to implement changes in the structure and
content of the application. Completing the usability testing will be important in order to
ensure the application is capable of effectively achieving its intended objective.
The evaluation process of young infants suspected of having meningitis can be
complex. Clinicians must consider all of these factors in decision-making: 1) variation of
clinical presentations; 2) importance of acting in a timely fashion; 3) determination of the
optimal testing strategy; 4) limitations of current diagnostics; 5) invasiveness of the
lumbar puncture; 6) amount and level of information parents need to effectively
participate in shared decision-making. The four projects described in this thesis aim to
address several of these areas that are important for the evaluation, diagnosis, parental
experience, and decision-making during the evaluation of infants ≤60 days of age with
concern for meningitis.
Further work is essential to better understand the presentation of infants in the
first 2 month of life with bacterial meningitis. Additional research is fundamental to
continue assessing the impact of new diagnostic technologies, such as the ME panel, in
overall patient care. The development of a parent-reported outcome measure will give
medical providers the ability to assess and continuously improve on the care they provide
during the evaluation of infants suspected of having meningitis. Further testing and
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implementation of the described software application will facilitate communication and
shared decision-making with parents of febrile infants during the evaluation process.
The concepts and ideas explored on these projects could also have potential
applications in other populations, such as in different age groups. In addition, the process
of understanding parental experiences or the implementation of software applications in
patient care could also serve as valuable resources for parents of children being evaluated
for other medical conditions.
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TABLES
Table 1. Interview Guide used for Parents of Febrile Infants ≤60 Days of Age Evaluated in the Emergency Department
Interview Topic

Interview Questions

Rapport building

Tell me about your baby. What are some of your favorite things to do with your baby?

Experience

-Why did you decide to bring your baby to the emergency room?
-What were you hoping would happen in the emergency room?
-What was your experience like in the emergency room from when you arrived to when you were
discharged/admitted to the hospital?
-What was good about the experience?
-What parts of the experience could have been better?
-How informed did you feel about what was happening in the emergency room?
-How involved did you feel in making decisions for your baby?
-How would you describe your feelings in the emergency room while your baby was being evaluated?
-What was stressful about being in the emergency room?
-What made the experience less stressful?
-What can nurses and doctors do to make the experience less stressful?
-Could you describe what a good experience in the emergency room with your baby would look like?
-Could you suggest any changes that would make the experience better for the next family with a baby with fever?

Satisfaction

Infant Outcomes

Family Outcomes

Ending Questions

If admitted:
-What has your experience been like being admitted to the hospital?
-How do you feel about your baby being in the hospital?
If discharged from the ED:
-What has your experience been like being home with your baby?
-How do you feel about being at home with your baby?
How satisfied do you feel about the medical care given to your baby in the emergency room? Please explain

How is your baby doing now? Tell me more about that
How do you know that your baby is doing well/not well?
What information do you use to know if your baby is doing well?
What is most important to you in deciding that your baby is doing well?
-How has your baby’s illness affected your family?
-Are you worried about the costs of the emergency room visit/admission? Please explain

Is there anything else you would like to add?

Associated Prompts

-Did you have any expectations about what would
happen in the emergency room?
-What were you expecting to happen in the
emergency room that would help your baby?
-What was the experience like with the nurses and
doctors? Tell me more about that
-What was the experience like when your baby
was having tests done? Tell me more about that
-Did your baby have a spinal tap? If YES, what
was that experience like?

-What helped your satisfaction the most?
-What could have made you more satisfied?
-How is your baby acting?
-How is your baby feeding?
-How is your baby sleeping?
- Did you or a family member have to miss work?
Please explain
-Did you need to find childcare? Please explain
-Did your baby’s illness cause you or your family
any financial problems? Please explain
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Table 2. Cerebrospinal Fluid Parameters of Infants ≤60 Days of Age with Bacterial Meningitis
Positive CSF
Gram Stain
Result, n/N
(%)

CSF
Pleocytosis
(Corrected),
n (%)

NeutrophilPredominant
CSF Among
Infants with
CSF
Pleocytosis
(Corrected),
n/N (%)
46/51 (90.2)b

Elevated
CSF Protein
Levels, n/N
(%)

Low CSF
Glucose
Levels, n/N
(%)

CSF
Pleocytosis
(Corrected)
or Positive
CSF Gram
Stain Result,
n (%)

Any
Abnormal
CSF
Parameter,
n (%)

Overall (n=66)
46/64 (71.9)a
53 (80.3)
46/63 (73.0)c
By Age Group
Age ≤28 days (n=44)
29/43 (67.4)a
35 (79.6)
29/33 (87.9)b
28/42 (67.7)c
Age 29-60 days (n=22) 17/21 (81.0)a
18 (81.8)
17/18 (94.4)
18/21 (85.7)c
d
P
0.38
1.0
0.65
0.14
Abbreviations: CSF, cerebrospinal fluid
a
Two infants had missing CSF Gram stain results
b
Two infants with corrected CSF pleocytosis had no CSF WBC differential
c
Three infants did not have a CSF protein or glucose level measurement
d
P value for comparison of parameter by age group (≤28 vs. 29-60 days)

31/63 (49.2)c

57 (86.4)

62 (93.9)

18/42 (42.9)c
13/21 (61.9)c
0.15

38 (86.4)
19 (86.4)
1.0

40 (90.9)
21 (95.5)
1.0
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Table 3. Characteristics of the 9 Infants with Bacterial Meningitis Who Had a Negative Gram Stain Result and No Corrected CSF
Pleocytosis
Age,
d

History of
Prematurity,
Yes or Noa

CSF
CSF
Blood
CSF
CSF
RBC
Protein Glucose
Culture
Culture
Count,
Level,
Level,
Result
Result
Cells
mg/dL mg/dL
per
mm3
b
10
No
No
23,900
6,955
0
8
2
684
58
No growth K. oxytoca
b
c
11
No
No
17,000
9,520
11
4
2
73
52
GBS
GBS
c
15
No
Yes
12,000 4,320
22
0
53,805
199
51
S. aureus
S. aureus
19
No
No
3,310b
1,324
1
0
243,500
313
55
No growth
E. coli
c
23
No
No
13,600 4,216
20
4
0
52
42
GBS
GBS
b
28
Yes
Yes
4,870
1,768
0
0
3,065
86
58
No growth
GBS
36
Yes
No
5,630
1,278
14c
3
225
197
52
GBS
GBS
42
No
No
10,950 4,599
˗d
0
62,778
589
41
E. coli
E. coli
b
43
Yes
Yes
21,500 17,200
0
8
6
86
39
No growth
GBS
Abbreviations: CSF, cerebrospinal fluid; WBC, white blood cell, ANC, absolute neutrophil count, ˗, not applicable.
a
Prematurity was defined as gestational age <37 weeks.
b
Abnormal values: WBC> 15,000 or <5,000 cells per µL.
c
Abnormal values: band percentage > 10%.
d
Band count not performed at this site.
Illappearing,
Yes or No

WBC
Count,
Cells
per µL

ANC,
Cells
per
mm3

Bands,
%

CSF WBC
Count,
Corrected,
Cells per
mm3
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Table 4. Targets of t;he BioFire® FilmArray® ME Panel
Viruses
Cytomegalovirus (CMV)
Enterovirus (EV)
Herpes Simplex Virus-1 (HSV-1)
Herpes Simplex Virus-2 (HSV-2)
Human Herpesvirus 6 (HHV-6)
Human Parechovirus (HPeV)
Varicella-Zoster Virus (VZV)

Bacteria
Escherichia coli K1
Haemophilus influenza
Listeria monocytogenes
Neisseria meningitides
Streptococcus agalactiae
Streptococcus pneumoniae

Fungi
Cryptococcus neoformans/Cryptococcus gattii
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Table 5. Studies of the BioFire® FilmArray® ME Panel included in the 2019 Meta-Analysis
Study

Study Population

Leber et al. 66
Arora et al. 80
Lee et al. 70
Radmard et al. 65
Hanson et al. 98
Messacar et al. 75
Graf et al. 76
Piccirilli et al. 86

Pediatrics and Adults
Pediatrics
Pediatrics and Adults
Pediatrics and Adults
Pediatrics and Adults
Pediatrics
Pediatrics
Pediatrics and Adults

Total
Number
of
Samples
in the
Study
1560
62
42
705
342
138
133
63

Type of
Study

Overall
Sensitivity

Overall
Specificity

PPV

NPV

Positive
Likeliho
od Ratio
(LR+)

Negative
Likeliho
od Ratio
(LR-)

Prospective
Prospective
Prospective
Retrospective
Retrospective
Retrospective
Retrospective
Retrospective

94.2%
100.0%
60%
85.7%
91.8%
91.1%
92.5%
85.7%

97.7%
93.4%
100%
98.3%
88.3%
97.9%
100.0%
100.0%

74.8%
55.6%
100.0%
36.8%
88.4%
95.3%
100.0%
100.0%

99.6%
100.0%
86.7%
99.9%
91.7%
95.9%
93.0%
77.8%

41.6
15.3
N/A
52.2
7.8
43.3
N/A
N/A

0.06
0
0.40
0.13
0.09
0.09
0.07
0.14
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Table 6. Themes that Emerged After a Preliminary Review of Interviews Performed to Parents of Febrile Infants
Theme
Identified
Feeling
Informed

Representative Answers

- “We felt like we knew everything that they were going to do from front to back. There wasn’t anything they were doing that
they weren’t telling us about. As they were going along, they were kind of explaining everything, even the simple things like
using the light to try and find the vein and everything like that. It was very descriptive and everything in letting us know
exactly what they were doing.”
-“So I think the news of being admitted was a little shocking to both of us because he said it and neither of us said anything
for a few seconds because I think we were just so surprised. Just because – not that they hadn’t been communicating, but we
both just had that thought that we were going to be sent home and everything was going to be like, oh, this is nothing. But
then yeah, no, everything went very smoothly with being admitted.”
-“Almost like they – in a good way, they were repeating themselves, which is good because being that I was exhausted and I
was pretty much up the night before. Some things I heard, some things I didn’t. It just depends on who was talking. So it was
nice to get the repeat story and information. Then like, you know, the doctor would tell us something and then we would
Google it and look it up and have more questions when they came back. So I think we both felt very informed.”
Involvement -“Yes, I think that they definitely didn’t make them for me. They just gave me the pros and cons on like what, especially with
in Decisions the spinal tap, the benefits of it and you know the negative effects and the pros definitely outweighed the cons so we went
with that.”
-“I feel like that’s the way it’s been in the hospital. They just tell you instead of asking. I mean, they’re the doctors and
nurses. But it kind of just feels like, oh, he’s now admitted for three days without – I don't know if I should be consulted, but
they’re just like oh, he’s now admitted. So there’s never really like, a…do you want him admitted?”
-“Oh yeah. Definitely. It was all of our decision. You know? They would’ve done – if we really wanted to do the spinal tap at
that time, they would’ve done it. They gave us what they thought was best and what they had discussed and they let us make
our own choice.”
Stress
-“The nurses were wonderful. They gave me a break. They watched the baby and I could leave the room and catch my breath
and make my phone calls and prepare to be staying so that was great. We got right up here really quickly for a bed request.
The transition was really smooth, so that’s always good and then the staff up here were great too so everything went well.”
-“Just really to me, it was the not knowing. You know, they can't give us an answer if they don’t know. You’ve got to wait for
the cultures to come back, which is totally understandable. The other thing that kind of worried me, which they did go over
and like I said, they did a great job, was the spinal fluid tap. You know, that scares me because I know there’s a lot of nerves
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around the area and things like that. So that was very scary. But I mean, they were great. They let us stay in the room while
they did it. They had a good team in there doing it. So you know, that always makes a world of difference, especially when us
as new parents coming in and dealing with this, the whole thing is scary.”
-“He’s good. His fever is 99.5 this morning. He’s just been very sort of snuggly and quiet. He’s you know I think a little off, I
can tell from his personality – from the last 48 hours. He seems tired, but other than that, the temperature is down, there’s not
other symptoms, so we’re in close contact with the pediatrician’s office just to make sure everything is okay.”
-“She’s doing much better. Her fever has completely come down. The rash that she came in for is also completely gone,
which is good. We’re hoping we’re going home today. She said as long as she stays stable, we should be able to go home this
afternoon.”
-“He’s been doing fine. But definitely I can tell that the antibiotics already start to have some effect on him. He’s a little bit
more fussy. Yeah.”
-“Yeah, I mean, it’s a really good question. I think there will be a residual just automatic response next time she gets a fever.
Even if it’s like a couple months out and it’s totally normal for a cold or an ear infection. I think there’s going to be like that
residual, last time we went through this, it was terrible. But like, I personally am a psychologist and in my training, I did my
focus for a couple years was on pediatric behavioral health. And so I worked in hospitals and you know, I was on the staff
side to some degree for a while. So I remember right, sick kids on whatever spectrum of sick, even if they’re chronically ill,
having something that’s normal for them and not feeling medicalized is really healthy for them. That’s really important for
them to not just be a kid with a medical diagnosis.”
-“Well it was a lot. So I think yesterday was the first day that I kind of felt normal. So throughout the admission and I think
the couple days after, me personally, I was just having spontaneous crying fits and I knew cognitively that everything was
okay, you know? Odds of relapse are super small, but just the emotional load, I just couldn’t shake it. It was really heavy. It
really dug in there I think. For my husband, he was just beside himself in the hospital and yeah, he was able to resume in
normal, daily activities when we got home. I think he detached from the emotional fear a little bit faster than I did. But he
definitely was still feeling it. He just processed it differently. Then we have grandparents on both sides and they were both
really concerned obviously and shocked because nobody expected it and the fact that she got this, I guess according to the
pediatrician was just really, really rare. My three-year-old daughter, we explained it to her, you know, like bacteria and the
bad germs/good germs. You know, needing medicine and all of that. So she kind of got a concrete understanding of it, just
something for her to latch onto knowledge-wise to help her make sense of why her sister was in the hospital and why we were
gone for a short while.”
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Table 7. Potential Benefits and Limitations of the BioFire® FilmArray® ME Panel
Potential Benefits
-Faster turnaround time, diagnosis and definitive treatment/treatment
discontinuation 70,71,74
-Pathogen identification in culture-negative CSF samples from
patients with suspected bacterial meningitis 71,80,89-91
-Detection of organisms in CSF obtained after antimicrobial
pretreatment 71,80,81,87,88
-Enables simultaneous identification of co-infections on the same
sample 9,101
-Ability to test for multiple organisms simultaneously 63
-Facilitates proper administration of chemoprophylaxis for close
contacts 81
-Relatively small amount of CSF sample (minimum 0.2 mL) required
63

-Limited hands-on time and technical expertise necessary 23,68

Potential Limitations
-Concern for false positive and false negative tests 23,66,94-97,112
-Not all pathogens able to cause CNS infections are detected by the
panel 63,66,70,71,78,79,86,112
-Unable to provide antimicrobial susceptibilities 63,66
-Not intended for CSF samples obtained from indwelling CNS
medical devices 63
-Positive results do not exclude the possibility of a co-infection with
an organism not in the panel 63
-Relatively high cost of purchase ($35,550-$50,000), service
($4,000/year) and per test ($~200) 68,83,93
- Lower ability to detect viruses when compared to some singleplex
assays 75,94,100,101
-Positive results for herpesviruses may be due to latency or
reactivation of the virus with or without disease 66,94

